Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
20.18
+1.85 (10.09%)
At close: May 12, 2025, 4:00 PM
21.00
+0.82 (4.06%)
After-hours: May 12, 2025, 6:57 PM EDT
Celldex Therapeutics Revenue
Celldex Therapeutics had revenue of $695.00K in the quarter ending March 31, 2025, with 345.51% growth. This brings the company's revenue in the last twelve months to $7.56M, up 24.49% year-over-year. In the year 2024, Celldex Therapeutics had annual revenue of $7.02M with 1.99% growth.
Revenue (ttm)
$7.56M
Revenue Growth
+24.49%
P/S Ratio
176.93
Revenue / Employee
$40,640
Employees
186
Market Cap
1.34B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.02M | 137.00K | 1.99% |
Dec 31, 2023 | 6.88M | 4.53M | 192.02% |
Dec 31, 2022 | 2.36M | -2.29M | -49.32% |
Dec 31, 2021 | 4.65M | -2.77M | -37.30% |
Dec 31, 2020 | 7.42M | 3.85M | 107.61% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CLDX News
- 4 days ago - Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 days ago - Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease - GlobeNewsWire
- 2 months ago - Celldex Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 - GlobeNewsWire
- 2 months ago - Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 - GlobeNewsWire
- 2 months ago - Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis - GlobeNewsWire
- 6 months ago - Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases - GlobeNewsWire